Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20674123 | 0.76 | HTT (0.47) | HTTPTK2SLC2A1MAPT | |
| SCHEMBL22402418 | 0.75 | NUDT1 (0.36) | HTTPTK2SLC2A1 | |
| SCHEMBL21958684 | 0.73 | HTT (0.44) | HTTPTK2SLC2A1MAPT | |
| SCHEMBL24553744 | 0.73 | HTT (0.44) | HTTPTK2SLC2A1MAPT | |
| SCHEMBL15650845 | 0.71 | LRRK2 (0.39) | SLC2A1 | |
| SCHEMBL24224504 | 0.70 | HTT (0.41) | HTTPTK2SLC2A1MAPT | |
| SCHEMBL22693059 | 0.70 | SGK1 (0.36) | HTT | |
| SCHEMBL22693058 | 0.70 | KDM4E (0.34) | — | |
| SCHEMBL15651743 | 0.69 | MAPK1 (0.39) | SLC2A1 | |
| SCHEMBL19964519 | 0.68 | HTT (0.52) | HTTPTK2SLC2A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| WO-2022002118-A1 | FUSED-RING HETEROCYCLE DERIVATIVE AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2022-01-06 | — | — | WO | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844049-B2 | GLP-1R agonists and uses thereof | GLP1R, GPR119, GIPR | HTT 3952/4885PTK2 2175/4885SLC2A1 168/4885 |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | HTT 4062/4885PTK2 2557/4885SLC2A1 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.